New hope for Hard-to-Treat breast cancer: targeted radiation plus hormone therapy
NCT ID NCT05870579
First seen May 03, 2026 · Last updated May 18, 2026 · Updated 5 times
Summary
This early-phase study is testing a new drug combination for people with a specific type of advanced breast cancer (ER+, HER2-) that has stopped responding to standard hormone therapy. The treatment adds a targeted radioactive drug (177Lu-NeoB) to two existing hormone-blocking medications (ribociclib and fulvestrant). The main goal is to find the safest dose and see how well patients tolerate the combination. About 48 adults with this type of breast cancer will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Hoag Memorial Hospital Presbyterian
RECRUITINGNewport Beach, California, 92663, United States
Contact Email: •••••@•••••
Contact
-
MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact Email: •••••@•••••
Contact
-
Novartis Investigative Site
RECRUITINGGuangzhou, 510060, China
-
Novartis Investigative Site
RECRUITINGShanghai, 200032, China
-
Novartis Investigative Site
RECRUITINGTianjin, 300300, China
-
Novartis Investigative Site
RECRUITINGSaint-Cloud, Hauts De Seine, 92210, France
-
Novartis Investigative Site
RECRUITINGBordeaux, 33076, France
-
Novartis Investigative Site
RECRUITINGClermont-Ferrand, 63011, France
-
Novartis Investigative Site
RECRUITINGSaint-Herblain, 44805, France
-
Novartis Investigative Site
RECRUITINGStrasbourg, F 67085, France
-
Novartis Investigative Site
RECRUITINGCologne, North Rhine-Westphalia, 50937, Germany
-
Novartis Investigative Site
RECRUITINGErlangen, 91054, Germany
-
Novartis Investigative Site
RECRUITINGEssen, 45147, Germany
-
Novartis Investigative Site
RECRUITINGMünchen, 80377, Germany
-
Novartis Investigative Site
RECRUITINGGliwice, 44 101, Poland
-
Novartis Investigative Site
RECRUITINGPorto, 4200-072, Portugal
-
Novartis Investigative Site
RECRUITINGL'Hospitalet de Llobregat, Barcelona, 08907, Spain
-
Novartis Investigative Site
RECRUITINGBarcelona, 08035, Spain
-
Novartis Investigative Site
RECRUITINGBarcelona, 08036, Spain
-
Novartis Investigative Site
RECRUITINGMadrid, 28034, Spain
-
Novartis Investigative Site
RECRUITINGMadrid, 28040, Spain
-
UCLA Jonsson Comp Cancer Center
RECRUITINGLos Angeles, California, 90095, United States
Contact
Contact Email: •••••@•••••
-
University of Kansas Medical Center
RECRUITINGWestwood, Kansas, 66205, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
University of Pennsylvania
RECRUITINGPhiladelphia, Pennsylvania, 19104, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Utah Intermountain Medical Center
RECRUITINGMurray, Utah, 84107, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.